Navigation Links
Multiple Sclerosis (MS) Industry Trends and 2018 Market Opportunities Analyzed in New Research Report at MarketReportsOnline.com
Date:11/30/2013

Dallas, Texas (PRWEB) November 30, 2013

The report titled "Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)" provide an insight into the market dynamics and various trends and opportunities associated with the global multiple sclerosis market. The report analyzes the various causes and symptoms related to the prevalence of MS in patients. Further, the report analyzes the global market sizing and growth of multiple sclerosis in terms of revenue, number of patients and sales of effective drugs. Also, the domestic market of United States which is the largest contributor to the global multiple sclerosis market has been assessed. The report concludes with a brief discussion of major factors driving the global multiple sclerosis market and profiles major players like Teva, Biogen Idec, Merck KGaA, Bayer and Novartis. Complete report available at http://www.marketreportsonline.com/295943.html.

Geographical Coverage: Global and United States

Company Coverage: Teva, Biogen Idec, Merck KGaA, Bayer and Novartis
The global Multiple Sclerosis market is undergoing drastic change since the last few years. The rising diagnosis and treatment rate coupled with growing investment in research and development has played a key role in the determining the growth dynamics of the global Multiple Sclerosis (MS) market.

Currently, MS is known to affect an estimated 2.5 million people around the world with around 5000 new cases emerging each year. Since there is no particular cure or treatment for multiple sclerosis, the market is currently dominated by few drugs and medication like Copaxone, Avonex, Betaseron and Extavia which delay or reduce the progression of multiple sclerosis in individuals.

Purchase a copy of this report at http://www.marketreportsonline.com/contacts/purchase.php?name=295943.

Until the last year, MS market was led by self injectables drugs such as Capaxone and Avonex that caused side effects like swelling, anxiety, redness and difficult breathing. To address these shortcomings and side effects, pharmaceutical companies developed oral drugs that are considered safe and effective. With the beginning of 2013, oral drugs such as Gilenya and Aubagio witnessed rapid demand due to their higher efficacy and better results. In addition, there are many drugs down the pipeline that would change the dynamics and growth of the multiple sclerosis market in future. For instance, Teva hopes its Copaxone successor, laquinimod, may help it preserve some market share when Copaxone loses patent protection.

Few Points from Table of Contents (http://www.marketreportsonline.com/295943-toc.html .) listed below:
1. Executive Summary
2. Global Multiple Sclerosis Market: An Overview
3. Global Multiple Sclerosis Market: An Analysis
4. Multiple Sclerosis Market: Country Analysis
5. Growth Drivers of Multiple Sclerosis Market
6. Company Profiles: Multiple Sclerosis Market

List of Figures
Figure 1: Multiple Sclerosis Diagrammatic Overview
Figure 2: Global Multiple Sclerosis Market Size, 2007-12 (US$ Million)
Figure 3: Global Multiple Sclerosis Market Size Forecast, 2013-18 (US$ Million)
Figure 4: Global Multiple Sclerosis Patients, 2007-12
Figure 5: Global Multiple Sclerosis Patients Forecast, 2013-18
Figure 6: Global Multiple Sclerosis Market, By Major Players, By Value (2012)
Figure 7: Global Multiple Sclerosis Market Share Analysis, By Geography, 2007-12
Figure 8: Global Multiple Sclerosis Competitor Share shift, 2013-16
Figure 9: Average Revenue per Patient, By Region, 2007-2012 (US$ Thousands)
Figure 10: United states Multiple Sclerosis Market, 2007-12 (US$ Million)
Figure 11: United states Multiple Sclerosis Market Forecast, 2013-18 (US$ Million)
Figure 12: United States Multiple Sclerosis Patients, 2007-12
Figure 13: United States Multiple Sclerosis Patients Forecast, 2013-18
Figure 14: Number of Multiple Sclerosis Patients Worldwide, 2010-2016E
Figure 15: Global Healthcare Expenditure, 2007-2012 (US$ Trillion)
Figure 16: Copaxone Sales, By Region, FY'2011-FY'13
Figure 17: Biogen Idec Global Sales, 2008-2012 (US$ Million)
Figure 18: Global Rebif Sales, 2008-2012 (US$ Million)
Figure 19: Merck Rebif Sales, By Region (2012)
Figure 20: Global Betaseron Sales, 2008-2012 (US$ Million)
Figure 21: Bayer's Pharmaceuticals Global Sales, By Region (2012)
Figure 22: Global Extavia Net Sales, 2008-2012 (US$ Million)
Table 1: Most Common Drugs used for Treating Multiple sclerosis
Table 2: Product Sales of Avonex & Tysabri, 2008-12 (US$ Million)

Explore more reports on Pharmaceuticals market @ http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.

About Us:
MarketReportsOnline.com is an online database of regional industry research reports, company profiles and SWOT analysis studies for multiple industries, organizations and market segments. Our sales and research experts offer 24 X 7 supports to our customers through phone and email communication.

Read the full story at http://www.prweb.com/releases/global-multiple-sclerosis/market/prweb11380179.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientists uncover multiple faces of deadly breast cancer
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Multiple thought channels may help brain avoid traffic jams
7. Study shows benefit of new maintenance therapy for multiple myeloma
8. FDA Issues Multiple Sclerosis Drug Alert
9. Pot Might Help Ease Multiple Sclerosis Symptoms
10. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
11. Multiple sclerosis patients have lower risk of cancer: UBC-VCH research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: